Bill Would Cut Use Of 30-Month Stay In Drug Suits

Law360, New York (March 6, 2006, 12:00 AM EST) -- Proposed legislation on Capitol Hill would raise the stakes in disputes between the pharmaceutical industry and generic drug manufacturers, with approval sure to reduce court-approved delays that keep generics off the market while being litigated.

Senate bill 2300, the “Lower Priced Drugs Act,” is intended to stem suspected abuse by the pharmaceutical industry of the 30-month stay. The stay is often granted to prevent approval of generic drugs by the U.S. Food and Drug Administration until the lawsuit is resolved.

The bill would also cut in...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.